Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 220 participants.
Also called NCT04075981
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 220 participants
- Registry
-
NCT04075981
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04075981. Randomized; triple masking; primary purpose treatment. Start 2019-09-30 (actual); primary completion 2025-10-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
- Acronym
- BOTAF
- Condition
- Cardiac Surgery
- Intervention (Drug)
- Botulinum Toxin Type A Injection [Xeomin]
- Intervention (Other)
- Drug placebo
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Merz Pharmaceuticals
- Collaborator
- Ministry of Health, France
Record details
- Record id
cardio:ct-nct04075981- Content hash
bb8c495249ddc6c0a69903bc0ecedadf2637b4eb274f2523c0a2e95d2af2cba1